1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity

MLA

Wei Qiu, et al. “1403-A PTPN2/N1 Inhibitor ABBV-CLS-484 Unleashes Potent Anti-Tumor Immunity.” Journal for ImmunoTherapy of Cancer, vol. 11, no. Suppl 2, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-SITC2023.1403-A.

APA

Wei Qiu, Qi Sun, Yi Yang, Chirag Patel, Meng Sun, Yue Liu, Kyle Halliwill, Sarah Kim, Rebecca Mathew, Jennifer M Frost, Jennifer A Roth, Domenick Kennedy, Robert T Manguso, Kathleen B Yates, Hakimeh Ebrahimi-Nik, Christina K Baumgartner, Arvin Iracheta-Vellve, Keith M Hamel, Kira Olander, … Philip R Kym. (2023). 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity. Journal for ImmunoTherapy of Cancer, 11(Suppl 2). https://doi.org/10.1136/jitc-2023-SITC2023.1403-A

Chicago

Wei Qiu, Qi Sun, Yi Yang, Chirag Patel, Meng Sun, Yue Liu, Kyle Halliwill, et al. 2023. “1403-A PTPN2/N1 Inhibitor ABBV-CLS-484 Unleashes Potent Anti-Tumor Immunity.” Journal for ImmunoTherapy of Cancer 11 (Suppl 2). doi:10.1136/jitc-2023-SITC2023.1403-A.